SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABS) was the target of a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 692,700 shares, a growth of 39.2% from the September 30th total of 497,500 shares. Based on an average trading volume of 275,100 shares, the days-to-cover ratio is currently 2.5 days. Currently, 8.0% of the company’s stock are sold short. Currently, 8.0% of the company’s stock are sold short. Based on an average trading volume of 275,100 shares, the days-to-cover ratio is currently 2.5 days.

SAB Biotherapeutics Price Performance

NASDAQ:SABS remained flat at $3.25 during trading hours on Monday. The company’s stock had a trading volume of 207,532 shares, compared to its average volume of 540,085. The firm’s fifty day simple moving average is $2.38 and its 200-day simple moving average is $2.12. The stock has a market capitalization of $33.83 million, a PE ratio of -0.81 and a beta of 0.60. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.87 and a current ratio of 0.87. SAB Biotherapeutics has a 52-week low of $1.00 and a 52-week high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last announced its earnings results on Thursday, August 7th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.27). As a group, research analysts predict that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in SAB Biotherapeutics stock. HB Wealth Management LLC bought a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 307,500 shares of the company’s stock, valued at approximately $618,000. HB Wealth Management LLC owned 2.95% of SAB Biotherapeutics at the end of the most recent quarter. Institutional investors own 7.82% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of SAB Biotherapeutics in a research note on Tuesday, October 14th. Leerink Partners assumed coverage on shares of SAB Biotherapeutics in a research note on Wednesday, September 17th. They issued an “outperform” rating and a $7.00 price target for the company. Chardan Capital reiterated a “buy” rating and issued a $12.00 price objective on shares of SAB Biotherapeutics in a report on Friday, September 19th. Wall Street Zen upgraded SAB Biotherapeutics to a “sell” rating in a report on Saturday, September 20th. Finally, HC Wainwright dropped their price objective on SAB Biotherapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.33.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.